SCHEMBL16740748

SCHEMBL16740748

CCc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc(C#N)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 7/20 0.48
PIK3CA P42336 8/20 0.47
MTOR P42345 8/20 0.47
PIK3CD O00329 7/20 0.47
PIK3CB P42338 7/20 0.47
PIK3CG P48736 7/20 0.47
TNKS O95271 1/20 0.41
RPS6KB1 P23443 1/20 0.40
GSK3B P49841 1/20 0.40
IDH1 O75874 1/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740792 0.89 PIK3CD (0.50) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740798 0.88 BMI1 (0.60) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740874 0.86 BMI1 (0.50) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740714 0.86 BMI1 (0.50) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740721 0.84 BMI1 (0.63) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740765 0.84 BMI1 (0.63) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740833 0.81 PIK3CA (0.52) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740887 0.81 BMI1 (0.65) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16748443 0.81 BMI1 (0.45) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740735 0.79 PIK3CA (0.44) BMI1PIK3CAMTORPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885PIK3CA 3534/4885MTOR 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.